Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects
NCT ID: NCT06485245
Last Updated: 2025-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
80 participants
INTERVENTIONAL
2025-04-22
2025-12-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects
NCT06573528
the Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects in Adult Subjects With Elevated LDL-C
NCT06132360
A Research Study Investigating How NNC0385-0434 is Tolerated in People With or Without High Cholesterol Levels
NCT04058834
A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia
NCT02087917
A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia
NCT01651273
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A1: 0.2mg CS060304
Healthy subjects in a fasting state will receive a single dose of CS060304 0.2 mg or placebo.
CS060304
Tablets administered orally
Cohort A2: 1mg CS060304
Healthy subjects in a fasting state will receive a single dose of CS060304 1 mg or placebo.
CS060304
Tablets administered orally
Cohort A3: 4mg CS060304
Healthy subject in fasted state receive a single oral dose of CS060304 4 mg or placebo on day 1, followed by a 4 day washout period, subjects in fed state will receive the same single oral dose of CS060304 4mg or placebo on day 5.
CS060304
Tablets administered orally
Cohort A4: 10mg CS060304
Healthy subjects in a fasting state will receive a single dose of CS060304 10 mg or placebo.
CS060304
Tablets administered orally
Cohort A5: 20mg CS060304
Healthy subjects in a fasting state will receive a single dose of CS060304 20 mg or placebo.
CS060304
Tablets administered orally
Cohort A6: 40mg CS060304
Healthy subjects in a fasting state will receive a single dose of CS060304 40 mg or placebo.
CS060304
Tablets administered orally
Cohort B1: 2mg CS060304
Elevated LDL-C subjects will receive the CS060304 2 mg or placebo once daily for a consecutive 14 days.
CS060304
Tablets administered orally
Cohort B2: 5mg CS060304
Elevated LDL-C subjects will receive the CS060304 5 mg or placebo once daily for a consecutive 14 days.
CS060304
Tablets administered orally
Cohort B3: 10mg CS060304
Elevated LDL-C subjects will receive the CS060304 10 mg or placebo once daily for a consecutive 14 days.
CS060304
Tablets administered orally
Cohort B4: 20mg CS060304
Elevated LDL-C subjects will receive the CS060304 20 mg or placebo once daily for a consecutive 14 days.
CS060304
Tablets administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CS060304
Tablets administered orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Sign and date the ICF.
2. Signing ICF age≥18 years≤55 years, male or female.
3. Weight: Male≥50kg, female≥45kg BMI: 18\~28kg/m².
4. Female or male subjects must be eligible for contraception during the study and for three months after the last dose.
5. Normal renal function.
6. Good general health.
7. No significant medical history, in good general health as assessed by the study during the Screening Period and no more than 28 days from the first dose.
8. Understand and comply with study procedures and limitations.
MAD
1. Sign and date the ICF.
2. Signing ICF age≥18 years≤65 years, male or female.
3. Weight: Male≥50kg, female≥45kg BMI: 18\~35kg/m².
4. Screening period, fasting LDL-C \> 110 mg/dL (2.85 mmol/L).
5. Female or male subjects must be eligible for contraception during the study and for three months after the last dose.
6. Normal renal function.
7. Good general health.
8. No significant medical history, in good general health as assessed by the study during the Screening Period and no more than 28 days from the first dose.
9. Understand and comply with study procedures and limitations. -
Exclusion Criteria
1. Special dietary requirements, not following a uniform diet.
2. Pregnant or nursing females or females who have pregnancy plans during the trial or within 3 months after the trial.
3. History of febrile illness or active infection within 7 days prior to first dose.
4. Positive urine drug screens at screening or baseline.
5. History of substance/drug abuse in the 5 years prior to the start of the trial, or a positive screening or baseline drug screen result.
6. History of previous corrected QT interval (QTc) prolongation:
1. Screening periods QTcF ≥ 450 ms.
2. Family history of hypocalcaemia or long QT interval syndrome.
3. Use of drugs causing QT/QTc prolongation.
4. Investigator judgement of clinically significant abnormal ECG results.
7. Abnormal liver function: AST, ALT, ALP, GGT and TBIL\>ULN.
8. Smoking or use of nicotine products within 3 months prior to screening and during the study period.
9. Use of other investigational drugs 40 days prior to enrolment or within at least 5 half-lives of drug use.
10. Positive screening results for infectious diseases during the screening period, include HIV, HBsAg, HBcAb, HCV antibody tests.
11. Any abnormal results of laboratory tests judged by the investigator to be clinically significant during the screening period.
12. Blood loss within 40 days prior to administration 50\~500 mL, or loss of more than 500 mL of blood within 56 days prior to administration.
13. Men and women who consumed more than 1 unit per day prior to screening. \[1 unit = 150 ml of wine, 360 ml of beer or 45 ml of 40% alcohol\]. Subjects will not be permitted to consume alcohol 48 hours prior to dosing and while in the CRU.
14. Prescription and over-the-counter use within 14 days or at least 5 half-lives prior to the baseline period, or use of any drug or other substance that may affect CYP3A activity within 14 days or at least 5 half-lives before taking this study drug.
15. History of thyroid disease or clinically significant thyroid test abnormalities.
16. Allergy to thyroid medication.
17. Presence of any disease that may interfere with the absorption, distribution, metabolism or excretion of drugs, Including bile salt metabolism in the colon, such as gastrectomy, inflammatory bowel disease, etc.
18. According to the researcher's judgment, there are clinically significant diseases found, including but not limited to (gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental or cardiovascular diseases), researchers believe that participating in the study poses risks to participants.
19. Allergy to the investigational drug or any component of the investigational drug, Allergy history and constitution.
20. Diseases or conditions with clinical significance that researchers believe may pose a risk to the safety of subjects or interfere with the conduct, progress, or completion of the study.
21. Abnormal thyroid function test during screening.
22. Screening or baseline cardiac troponin\>ULN.
MAD
1. Special dietary requirements that cannot follow a unified diet.
2. Pregnant or lactating women who have a pregnancy plan during or within 3 months after the trial, female subjects tested positive for pregnancy during screening or baseline period.
3. Individuals with a history of febrile diseases or active infections within 7 days prior to the first administration of medication.
4. Positive urine drug screening results during screening or baseline period.
5. History of drug/drug abuse within 5 years prior to the start of the trial, or positive drug screening results during screening or baseline period.
6. Subjects who are receiving lipid-lowering treatment or have LDL-C\>190 mg/dL and have a family history of coronary heart disease, arrhythmia, unexplained syncope, or cardiac arrest.
7. Existing history of QTc extension in the past:
1. Screening period QTcF ≥ 450 ms.
2. Family history of hypocalcemia or long QT interval syndrome.
3. Using drugs that cause QT/QTc prolongation.
4. Abnormal results of ECG with clinical significance determined by researchers.
8. Abnormal liver function: AST, ALT, ALP, GGT and TBIL\>ULN.
9. Screening for smoking or using nicotine products within the first 3 months and during the study period.
10. Use of other investigational drugs 40 days prior to enrolment or within at least 5 half-lives of drug use.
11. Positive screening results for infectious diseases during the screening period, include HIV, HBsAg, HBcAb, HCV antibody Tests.
12. Any abnormal results of laboratory tests judged by the investigator to be clinically significant during the screening period.
13. Blood loss within 40 days prior to administration 50\~500 mL, or loss of more than 500 mL of blood within 56 days prior to administration.
14. Men and women who consumed more than 1 unit per day prior to screening. \[1 unit = 150 ml of wine, 360 ml of beer or 45 ml of 40% alcohol\]. Subjects will not be permitted to consume alcohol 48 hours prior to dosing and while in the CRU.
15. Prescription and over-the-counter use within 14 days or at least 5 half-lives prior to the baseline period, or use of any drug or other substance that may affect CYP3A activity within 14 days or at least 5 half-lives before taking this study drug.
16. History of thyroid disease or clinically significant thyroid test abnormalities.
17. Allergy to thyroid medication.
18. Presence of any disease that may interfere with the absorption, distribution, metabolism or excretion of drugs, Including bile salt metabolism in the colon, such as gastrectomy, inflammatory bowel disease, etc.
19. According to the researcher's judgment, there are clinically significant diseases found, including but not limited to (gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental or cardiovascular diseases), researchers believe that participating in the study poses risks to participants.
20. Allergy to the investigational drug or any component of the investigational drug, Allergy history and constitution.
21. Diseases or conditions with clinical significance that researchers believe may pose a risk to the safety of subjects or interfere with the conduct, progress, or completion of the study.
22. Abnormal thyroid function test during screening.
23. Screening or baseline cardiac troponin\>ULN.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cascade Pharmaceuticals, Inc
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CS060304-FIH-CN-I-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.